AAVrh.10 immunogenicity in mice and humans. Relevance of antibody cross-reactivity in human gene therapy

Gene Therapy

Volumn 22, Issue 2, 2015, Pages 196-201

  Thwaite, R ^a   Pages G ^a   Chillon M ^a,b   Bosch, A ^a  

^a UNIVERSITAT AUTÒNOMA DE BARCELONA   (Spain)

^b INSTITUCIÓ CATALANA DE RECERCA I ESTUDIS AVANÇATS ICREA   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

ADENO ASSOCIATED VIRUS 2 ANTIBODY; ADENO ASSOCIATED VIRUS 9 ANTIBODY; ADENO ASSOCIATED VIRUS SEROTYPE RH.10 ANTIBODY; ADENO ASSOCIATED VIRUS SEROTYPE RH.10 VECTOR; CROSS REACTING ANTIBODY; IMMUNOGLOBULIN G; IMMUNOGLOBULIN G ANTIBODY; NEUTRALIZING ANTIBODY; PARVOVIRUS VECTOR; UNCLASSIFIED DRUG; VIRUS ANTIBODY; PROTEIN BINDING;

ADENO ASSOCIATED VIRUS; ADENO ASSOCIATED VIRUS 2; ADENO ASSOCIATED VIRUS 9; ADENO ASSOCIATED VIRUS SEROTYPE RH.10; ADULT; ANIMAL EXPERIMENT; ANTIBODY BLOOD LEVEL; ANTIBODY TITER; ANTIGEN BINDING; ANTIGEN RECOGNITION; ARTICLE; CONTROLLED STUDY; CROSS REACTION; HUMAN; HUMAN CELL; HUMORAL IMMUNITY; IMMUNOGENICITY; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; SEROPREVALENCE; SEROTYPE; SERUM; VIRAL GENE DELIVERY SYSTEM; ANIMAL; BLOOD; DEPENDOPARVOVIRUS; GENE THERAPY; GENETIC TRANSDUCTION; IMMUNOLOGY; INSTITUTE FOR CANCER RESEARCH MOUSE;

ADENO-ASSOCIATED VIRUS; ANIMALIA; MUS; SIMIAE;

ANIMALS; ANTIBODIES, VIRAL; CROSS REACTIONS; DEPENDOVIRUS; GENETIC THERAPY; HUMANS; MALE; MICE, INBRED ICR; PROTEIN BINDING; TRANSDUCTION, GENETIC;

EID: 84922399417     PISSN: 09697128     EISSN: 14765462     Source Type: Journal    
DOI: 10.1038/gt.2014.103     Document Type: Article

References (32)

1. Mingozzi F, High KA. Immune responses to AAV vectors: overcoming barriers to successful gene therapy. Blood 2013; 122: 23-36.
2. Calcedo R, Wilson JM. Humoral immune response to AAV. Front Immunol 2013; 4: 341.
3. Mays LE, Vandenberghe LH, Xiao R, Bell P, Nam HJ, Agbandje-McKenna M et al. Adeno-associated virus capsid structure drives CD4-dependent CD8+ T cell response to vector encoded proteins. J Immunol 2009; 182: 6051-6060.
4. Ciesielska A, Hadaczek P, Mittermeyer G, Zhou S, Wright JF, Bankiewicz KS et al. Cerebral infusion of AAV9 vector-encoding non-self proteins can elicit cell-mediated immune responses. Mol Ther 2013; 21: 158-166.
5. Samaranch L, San Sebastian W, Kells AP, Salegio EA, Heller G, Bringas JR et al. AAV9-mediated expression of a non-self protein in nonhuman primate central nervous system triggers widespread neuroinflammation driven by antigen-presenting cell transduction. Mol Ther 2014; 22: 329-337.
6. Grieger JC, Samulski RJ. Adeno-associated virus vectorology, manufacturing, and clinical applications. Methods Enzymol 2012; 507: 229-254.
7. Gao G, Alvira MR, Somanathan S, Lu Y, Vandenberghe LH, Rux JJ et al. Adeno-associated viruses undergo substantial evolution in primates during natural infections. Proc Natl Acad Sci USA 2003; 100: 6081-6086.
8. Sondhi D, Hackett NR, Peterson DA, Stratton J, Baad M, Travis KM et al. Enhanced survival of the LINCL mouse following CLN2 gene transfer using the rh.10 rhesus macaque-derived adeno-associated virus vector. Mol Ther 2007; 15: 481-491.
9. Piguet F, Sondhi D, Piraud M, Fouquet F, Hackett NR, Ahouansou O et al. Correction of brain oligodendrocytes by AAVrh.10 intracerebral gene therapy in metachromatic leukodystrophy mice. Hum Gene Ther 2012; 23: 903-914.
10. Homs J, Pages G, Ariza L, Casas C, Chillon M, Navarro X et al. Intrathecal administration of IGF-I by AAVrh10 improves sensory and motor deficits in a mouse model of diabetic neuropathy. Mol Ther Method Clin Dev 2014; 1: 7.
11. Wang H, Yang B, Qiu L, Yang C, Kramer J, Su Q et al. Widespread spinal cord transduction by intrathecal injection of rAAV delivers efficacious RNAi therapy for amyotrophic lateral sclerosis. Hum Mol Genet 2014; 23: 668-681.
12. Tardieu M, Zerah M, Husson B, de Bournonville S, Deiva K, Adamsbaum C et al. Intracerebral administration of adeno-associated viral vector serotype rh.10 carrying human SGSH and SUMF1 cDNAs in children with mucopolysaccharidosis type IIIA disease: results of a phase I/II trial. Hum Gene Ther 2014; 25: 506-516.
13. Perdomini M, Belbellaa B, Monassier L, Reutenauer L, Messaddeq N, Cartier N et al. Prevention and reversal of severe mitochondrial cardiomyopathy by gene therapy in a mouse model of Friedreich's ataxia. Nat Med 2014; 20: 542-547.
14. Boutin S, Monteilhet V, Veron P, Leborgne C, Benveniste O, Montus MF et al. Prevalence of serum IgG and neutralizing factors against adeno-associated virus (AAV) types 1, 2, 5, 6, 8, and 9 in the healthy population: implications for gene therapy using AAV vectors. Hum Gene Ther 2010; 21: 704-712.
15. Calcedo R, Vandenberghe LH, Gao G, Lin J, Wilson JM. Worldwide epidemiology of neutralizing antibodies to adeno-associated viruses. J Infect Dis 2009; 199: 381-390.
16. Homs J, Ariza L, Pages G, Udina E, Navarro X, Chillon M et al. Schwann cell targeting via intrasciatic injection of AAV8 as gene therapy strategy for peripheral nerve regeneration. Gene Ther 2011; 18: 622-630.
17. Foust KD, Nurre E, Montgomery CL, Hernandez A, Chan CM, Kaspar BK. Intravascular AAV9 preferentially targets neonatal neurons and adult astrocytes. Nat Biotechnol 2009; 27: 59-65.
18. Duque S, Joussemet B, Riviere C, Marais T, Dubreil L, Douar AM et al. Intravenous administration of self-complementary AAV9 enables transgene delivery to adult motor neurons. Mol Ther 2009; 17: 1187-1196.
19. Lieberman R, Stiffel C, Asofsky R, Mouton D, Biozzi G, Benacerraf B. Genetic factors controlling anti-sheep erythrocyte antibody response and immunoglobulin synthesis in backcross and F2 progeny of mice genetically selected for ?high? or ?low? antibody synthesis. J Exp Med 1972; 136: 790-798.
20. Chiuchiolo MJ, Kaminsky SM, Sondhi D, Hackett NR, Rosenberg JB, Frenk EZ et al. Intrapleural administration of an AAVrh.10 vector coding for human alpha1- antitrypsin for the treatment of alpha1-antitrypsin deficiency. Human gene therapy. Clin Dev 2013; 24: 161-173.
21. Gray SJ, Nagabhushan Kalburgi S, McCown TJ, Jude Samulski R. Global CNS gene delivery and evasion of anti-AAV-neutralizing antibodies by intrathecal AAV administration in non-human primates. Gene Ther 2013; 20: 450-459.
22. Samaranch L, Salegio EA, San Sebastian W, Kells AP, Foust KD, Bringas JR et al. Adeno-associated virus serotype 9 transduction in the central nervous system of nonhuman primates. Hum Gene Ther 2012; 23: 382-389.
23. Riviere C, Danos O, Douar AM. Long-term expression and repeated administration of AAV type 1, 2 and 5 vectors in skeletal muscle of immunocompetent adult mice. Gene Ther 2006; 13: 1300-1308.
24. Gurda BL, DiMattia MA, Miller EB, Bennett A, McKenna R, Weichert WS et al. Capsid antibodies to different adeno-associated virus serotypes bind common regions. J Virol 2013; 87: 9111-9124.
25. Tellez J, Van Vliet K, Tseng YS, Finn JD, Tschernia N, Almeida-Porada G et al. Characterization of naturally-occurring humoral immunity to AAV in sheep. PLoS One 2013; 8: e75142.
26. Bartel M, Schaffer D, Buning H. Enhancing the clinical potential of AAV vectors by capsid engineering to evade pre-existing immunity. Front Microbiol 2011; 2: 204.
27. Louis Jeune V, Joergensen JA, Hajjar RJ, Weber T. Pre-existing anti-adenoassociated virus antibodies as a challenge in AAV gene therapy. Hum Gene Ther Methods 2013; 24: 59-67.
28. Calcedo R, Morizono H, Wang L, McCarter R, He J, Jones D et al. Adeno-associated virus antibody profiles in newborns, children, and adolescents. Clin Vaccine Immunol 2011; 18: 1586-1588.
29. Wang L, Calcedo R, Wang H, Bell P, Grant R, Vandenberghe LH et al. The pleiotropic effects of natural AAV infections on liver-directed gene transfer in macaques. Mol Ther 2010; 18: 126-134.
30. Zolotukhin S. Production of recombinant adeno-associated virus vectors. Hum Gene Ther 2005; 16: 551-557.
31. Zolotukhin S, Byrne BJ, Mason E, Zolotukhin I, Potter M, Chesnut K et al. Recombinant adeno-associated virus purification using novel methods improves infectious titer and yield. Gene Ther 1999; 6: 973-985.
32. Treleaven CM, Tamsett TJ, Bu J, Fidler JA, Sardi SP, Hurlbut GD et al. Gene transfer to the CNS is efficacious in immune-primed mice harboring physiologically relevant titers of anti-AAV antibodies. Mol Ther 2012; 20: 1713-1723.